How do you see the importance of biobanking
developing between now and 2020?
We think that samples and the treatment of data obtained through
biobanking activities could be a way to revolutionise the pharmaceutical
market. Indeed, one of the aims of the pharmaceutical groups in investing
time and money into biobanking is to relevantly reduce the duration of
drug development and the number of necessary preclinical studies. To
achieve this, some researchers are starting to model the result of drug
actions by using the data collected through previous research studies.
What future developments do you see taking place?
Regarding our work as a biorepository service provider, we are convinced
that, over the next few years, operational and detailed radio frequency
Identification development, for example temperature and volume, will
significantly improve the ways to collect and manage biosamples.
Another major area will be the standardisation of analytical methods for
the evaluation of the sample quality. This is one of the major challenges
– how to evaluate the quality of the samples and how to determine their
degradation through time. But we also need to develop standard methods
for cryopreservation and samples processing.
Biobanking offers a wide range of innovative perspectives, but
standardisation and collaboration will be key to the success of this
research sector. Biobanking is identified as a costly actor in this domain,
and this therefore requires biobanking actors to innovate in order to
reduce its operating costs.
Everyone agrees on the need to standardise
biobanking activity, but interests and points of
view vary from one country to another. The
challenge for the working group and the ISO will
be to develop an ISO norm suiting the needs of
the biobanking market and accepted by every
actor involved in its application.
What recent efforts have been
made to overcome the difficulties
in the standardisation of the
identification and traceability of
data in the sector?
In France, the NFS 96-900 certification (French
certification for biological resource centre
(BRC)) activities was settled in 2002.
Nowadays, around 100 BRCs, Cell & Co
included, have been certified. This has
improved exchange between the BRCs and has
permitted them to establish qualitative
operational methods. The results produced and
the sample generated have better value and
allow the BRCs to work more easily with
This spreading of the NFS 96-900 certification
has been supported by ‘Infrastructure
Biobanques’, which was created in 2011 with
the help of the French Government.
What further attempts can be made
in overcoming these
In parallel to the establishment of the ISO for
biobanking, it appears necessary to work on the
establishment of a standard terminology that
would allow the biobanking actors and
database to cross their data more easily. This
work would have to be performed by targeted
pathology, by type of samples, by type of
projects, etc. Several attempts have been
performed with this aim, but this work is still
unachieved and must be extended.
What role do you see biobanking
playing in Horizon 2020?
Every clinical and cohort study performed
through Horizon 2020 should implicate the
generation of a qualitative biocollection that
might be valued by other researchers. The EU’s
research and innovation framework programme
has then a role to play in the evaluation of the
research schemes that do not anticipate this
need or underestimate the requirements,
notably in terms of a database and the
establishment of a valuable biocollection.
Cell & Co
B R OW S Ewww.cell-and-co.com
H O R I Z O N
2 0 2 0www.horizon2020projects.com
H O R I Z O N 2 0 2 0 P R O J E C T S : P O R TA L
I S S U E S E V E N
H E A L T H & P AT I E N T D ATA
currently a major